Wu Yunqiu, Quan Yi, Zhou Dan, Li Yixian, Wen Xue, Liu Jun, Long Wenbo
Department of Breast Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Department of Pathology, The Affiliated Hospital, Southwest Medical University, Jiangyang District, Taiping Street No. 25, Luzhou, China.
Clin Transl Oncol. 2025 Mar;27(3):988-999. doi: 10.1007/s12094-024-03663-6. Epub 2024 Aug 22.
The dysregulation of the cytoplasmic poly(A)-binding protein 1 (PABPC1) is involved in a variety of tumors but little is known about its role in human breast cancer. Therefore, the effect of PABPC1 in the prognosis and regimen selection in breast cancer patients was evaluated.
A total of 791 cases of invasive breast cancer were included in this study, although only 416 were involved in subsequent analyses after the propensity score matching (PSM) test. PABPC1 expression was detected by immunohistochemistry. The relationship between PABPC1 expression and clinicopathological factors, postoperative regimens, and outcomes was determined.
In the total 791 cases, 583 cases were positive for PABPC1, but only 212 (26.8%) showed high PABPC1 expression (PABPC1-HE). The overall survival (OS) and disease-free survival (DFS) of PABPC1-HE patients after PSM were significantly worse than those in patients with PABPC1 low expression (PABPC1-LE), regardless of age, molecular type, tumor size, nodal status, or pStage. Postoperative chemotherapy (CT) increased the OS of PABPC1-HE patients but not that of PABPC1-LE patients. Among patients receiving endocrine therapy, those in the PABPC-LE group had an extended OS, while CT or chemoradiotherapy (CT/CRT) only significantly extended the OS time of PABPC-HE patients. CT/CRT did not significantly extend the survival of PABPC1-LE HER2-positive patients but extended the OS of PABPC1-HE HER2-positive patients. However, the OS of patients treated with CT/CRT + trastuzumab therapy was significantly longer than that of other patients under other therapies in the PABPC1-HE group, suggesting that PABPC1-HE might be sensitive to trastuzumab-based therapy. The multivariate analysis revealed that PABPC1-HE was an independent prognostic factor for both poor OS and DFS in breast cancer except luminal A type.
Our results revealed that PABPC1 might be considered as a biomarker to help in subtyping, as well as in the prognosis and regimen selection of breast cancer patients.
细胞质聚腺苷酸结合蛋白1（PABPC1）失调与多种肿瘤相关，但对其在人类乳腺癌中的作用知之甚少。因此，评估了PABPC1对乳腺癌患者预后及治疗方案选择的影响。
本研究共纳入791例浸润性乳腺癌患者，经倾向评分匹配（PSM）检验后，仅416例纳入后续分析。采用免疫组织化学法检测PABPC1表达。确定PABPC1表达与临床病理因素、术后治疗方案及预后的关系。
在791例患者中，583例PABPC1呈阳性，但仅212例（26.8%）表现为PABPC1高表达（PABPC1-HE）。PSM后，PABPC1-HE患者的总生存期（OS）和无病生存期（DFS）均显著差于PABPC1低表达（PABPC1-LE）患者，无论年龄、分子类型、肿瘤大小、淋巴结状态或病理分期如何。术后化疗（CT）可提高PABPC1-HE患者的OS，但对PABPC1-LE患者无效。在内分泌治疗患者中，PABPC-LE组患者的OS延长，而CT或放化疗（CT/CRT）仅显著延长PABPC-HE患者的OS时间。CT/CRT并未显著延长PABPC1-LE HER2阳性患者的生存期，但延长了PABPC1-HE HER2阳性患者的OS。然而，在PABPC1-HE组中，接受CT/CRT联合曲妥珠单抗治疗的患者的OS显著长于接受其他治疗的患者，提示PABPC1-HE可能对基于曲妥珠单抗的治疗敏感。多因素分析显示，除腔面A型外，PABPC1-HE是乳腺癌患者OS和DFS不良的独立预后因素。
我们的结果表明，PABPC1可作为一种生物标志物，有助于乳腺癌的亚型分类、预后评估及治疗方案选择。
